{
  "id": "2247620651_1",
  "title": "百济神州研发日：未来 18 个月，预计将迎来 20 项里程碑进展",
  "content": "<div class=\"rich_media_content js_underline_content autoTypeSetting24psection\" id=\"js_content\">\n <section data-mpa-action-id=\"m9uot5bs981\" data-pm-slice=\"0 0 []\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <a class=\"weapp_image_link js_weapp_entry\" data-miniprogram-appid=\"wx33d4c3735820a33e\" data-miniprogram-applink=\"\" data-miniprogram-imageurl=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgmyicDLwjjVmU0j3AaTPibClFMOibXPLEdw2AcHCYfiaOh6bLxzWzdJwllQ/640?wx_fmt=png&amp;from=appmsg\" data-miniprogram-nickname=\"Insight医药情报助手\" data-miniprogram-path=\"pages/index/index\" data-miniprogram-servicetype=\"0\" data-miniprogram-type=\"image\" style=\"\">\n   <img class=\"rich_pages wxw-img\" data-croporisrc=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgmyicDLwjjVmU0j3AaTPibClFMOibXPLEdw2AcHCYfiaOh6bLxzWzdJwllQ/0?wx_fmt=png&amp;from=appmsg\" data-cropselx2=\"562\" data-cropsely2=\"148\" data-imgfileid=\"100133271\" data-ratio=\"0.26382978723404255\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgmyicDLwjjVmU0j3AaTPibClFMOibXPLEdw2AcHCYfiaOh6bLxzWzdJwllQ/640?wx_fmt=png&amp;from=appmsg\"/>\n  </a>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mceg0ffd1sx4\" leaf=\"\" style=\"font-size: 15px;\">\n   6 月 26 日，百济神州举行了投资者研发日活动。会上，百济神州高层领导团队、资深研发负责人以及行业意见领袖，从多维度阐述了百济神州的科学战略和执行能力。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mceg0ffd1sx4\" leaf=\"\" style=\"font-size: 15px;\">\n   百济神州正处于发展的关键时期，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    目前拥有 40 多款处于临床开发和商业化阶段的产品。未来 18 个月内，预计将迎来 20 项里程碑进展\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mceg0ffd1sx4\" leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-bottom: 8px;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"52\" data-backw=\"463\" data-imgfileid=\"502448861\" data-ratio=\"0.11296296296296296\" data-type=\"png\" data-w=\"1080\" height=\"52\" src=\"/static/res/logo/https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZaqU9L6wBSPRicxbyNQUGkONWicTcnJOwMEFTtWTw62FMicjoVatWfAvaicG6L4TcSgNlgR0Q54oPWYdg/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1\" style=\"-webkit-tap-highlight-color: transparent;margin-top: 0px;margin-right: 0px;margin-left: 0px;padding: 0px;outline: 0px;max-width: 100%;vertical-align: bottom;color: rgba(0, 0, 0, 0.9);font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;orphans: 2;text-align: center;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 1080px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-family: 等线;font-size: 16px;letter-spacing: 0.578px;width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;visibility: visible !important;\" width=\"463\"/>\n  </span>\n </p>\n <p data-mpa-action-id=\"mceg20gg12f1\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mceg20fv1svz\" style=\"line-height: 1.75em;text-align: center;font-size: 17px;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    研发战略\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   据百济神州全球研发负责人汪来博士介绍，公司的整体研发战略包括四个方面：1）在重点疾病领域开发深厚且具有影响力的产品组合；2）「快速概念验证」实现价值最大化；3）尽早启动联合治疗实现速赢；4）将最具变革意义的药物推进至后期开发阶段\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   百济神州的临床前项目和自研新分子实体数量在连年攀升。2011-2018 年，临床前项目的平均数为 7 个，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    到 2025 年这一数字已达到 82 个\n   </span>\n   。进入临床的自研新分子实体数量方面，2013-2018 年的平均数只有 1 个，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    到 2024 年底已达到 10 个\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"312\" data-backw=\"578\" data-imgfileid=\"100136938\" data-ratio=\"0.53984375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcQpFXcSkfE4JfHK9nO2Xd9G3iaVV0M83nYAKbATCLnddwZFyjR96CTBA/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;text-align: center;\">\n  <span data-pm-slice=\"0 0 []\" style='color: rgb(178, 178, 178);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span leaf=\"\">\n    截图来源：百济神州研发日 PPT（下同）\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   值得注意的是，虽然百济神州开发的管线数量越来越多，但其仍在严控关键试验，只会将优质分子推进临床。对于未达高标准项目即时终止，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    在过去的 3.5 年中已终止 60+临床前项目\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"323\" data-backw=\"578\" data-imgfileid=\"100136939\" data-ratio=\"0.559375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcGccdk9guZezu0lNSVUNh0N12oWNBUiaHuFMaInGhf8arO6f38hwtPZQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   蛋白质降解是百济神州的研发重心之一，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    百济神州已在该领域开发 20 多个项目\n   </span>\n   ，包括\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    降解抗体偶联物\n   </span>\n   <span style=\"color: rgb(178, 178, 178);font-weight: bold;\" textstyle=\"\">\n    （DAC）\n   </span>\n   、\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    嵌合式降解激活化合物\n   </span>\n   <span style=\"color: rgb(178, 178, 178);font-weight: bold;\" textstyle=\"\">\n    （CDAC）\n   </span>\n   ，拟开发适应症涵盖血液肿瘤、实体瘤以及非肿瘤。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"275\" data-backw=\"578\" data-imgfileid=\"100136942\" data-ratio=\"0.4765625\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcEltwCG3eT0uzlau95Herow6jw9kZTZ5Bia8LfMTUWtyr5ELRiatEnDLg/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在 ADC 领域，百济神州已建立稳健的双 TAA 和新型有效载荷 ADC 管线，其中有 4 个项目已进入临床阶段，包括 B7-H4 ADC、B7-H3 ADC、CEA ADC、FGFR2b ADC。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"329\" data-backw=\"578\" data-imgfileid=\"100136943\" data-ratio=\"0.56953125\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcahyxdkibYpukPcd4Un52aXrfnatwhibRjPKJXJM56RfulgXWGBiarNiaDw/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在未来 3-6 年内，在 B 细胞恶性肿瘤、AML/MDS、乳腺癌/妇科癌、肺癌、胃肠道癌、免疫和炎症疾病领域\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    ，百济神州预计\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    将会把 8-10 个高度差异化新分子实体推进到临床试验阶段\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"258\" data-backw=\"578\" data-croporisrc=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcLajdjAw7Syovu0d0hPLTj6ib7uR1bLia2zsuAfDibvARveHJqV2utWO2Q/640?wx_fmt=png&amp;from=appmsg\" data-cropx2=\"1080\" data-cropy2=\"422.7758007117437\" data-imgfileid=\"100136944\" data-ratio=\"0.39166666666666666\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_jpg/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPceWQFnEDDxyeA2oHdGic9fJbHTiaKiaDiauLib8yAwTiamy7PGOyvA2D65Thg/640?wx_fmt=jpeg\" style=\"width: 1080px;height:220px;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在药物研发中，百济神州一直注重优化药物开发流程。目前，从启动 GLP 毒性研究至 1a 期首例患者入组，平均用时只需要 9.9 个月；每个剂量递增队列平均用时只需 7.1 周；确定推荐剂量后，启动剂量扩展平均用时 4.4 周。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"319\" data-backw=\"578\" data-imgfileid=\"100136945\" data-ratio=\"0.55234375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPc5vsibSWX7t9nib8jC07J0bJ075LUxyrRxwato2OprLtDlaTnYwpUibIug/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   百济神州现拥有 1200+名科研人员，覆盖多样化的治疗模式。在「去 CRO 化」运营模式下，充分利用自动化和 AI 技术，最大限度提升临床试验效率。\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   截至 5 月 28 日，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    百济正在进行临床开发的产品有 30 个，进行中的临床试验有 96 项\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"259\" data-backw=\"578\" data-imgfileid=\"100136946\" data-ratio=\"0.4484375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcTH37EX0wXhO5Fpicz21muWplckkj1ZHgCglkSfiazlr6nShqMelo6F6Q/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-bottom: 8px;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"52\" data-backw=\"463\" data-imgfileid=\"502448861\" data-ratio=\"0.11296296296296296\" data-type=\"png\" data-w=\"1080\" height=\"52\" src=\"/static/res/logo/https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZaqU9L6wBSPRicxbyNQUGkONWicTcnJOwMEFTtWTw62FMicjoVatWfAvaicG6L4TcSgNlgR0Q54oPWYdg/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1\" style=\"-webkit-tap-highlight-color: transparent;margin-top: 0px;margin-right: 0px;margin-left: 0px;padding: 0px;outline: 0px;max-width: 100%;vertical-align: bottom;color: rgba(0, 0, 0, 0.9);font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;orphans: 2;text-align: center;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 1080px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-family: 等线;font-size: 16px;letter-spacing: 0.578px;width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;visibility: visible !important;\" width=\"463\"/>\n  </span>\n </p>\n <p data-mpa-action-id=\"mceg7dja1dt6\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mceg7dilrcj\" style=\"line-height: 1.75em;text-align: center;font-size: 17px;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    血液肿瘤产品组合\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在血液肿瘤治疗领域，百济神州目前拥有第二代共价 BTK 抑制剂\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    百悦泽\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （泽布替尼）\n   </span>\n   、新一代 BCL2 抑制剂\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    索托克拉\n   </span>\n   ，以及 BTK CDAC 抑制剂\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    BGB-16673\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   CLL 是百济血液瘤的主攻领域。虽然全球已有许多新型治疗方法获批治疗 CLL，但接受一线治疗后出现复发的患者不断增多，仍面临大量未满足需求。百济神州\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    是\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    唯一一家在 3 个 CLL 基础作用机制中均拥有潜在 BIC 产品的公司\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"263\" data-backw=\"578\" data-imgfileid=\"100136948\" data-ratio=\"0.45546875\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPc7C1fD7qQ70TREmBskHmeP4mZ1TE6Piaeyl8kwuxr1RFoskDngLPw7bQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在 CLL 适应症上，百济神州目前已拥有以百悦泽为基础的从三线/末线到一线的治疗方案。随着索托克拉、BGB-16673的开发，百济神州希望通过完全自主拥有的产品组合，解决 CLL 患者未满足的治疗需求。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"319\" data-backw=\"578\" data-croporisrc=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcHJsxWGAwxp0q78tiacAwX7lXqyibpSZLliaicdVXQuz968ZrFWiabJyibs8w/0?wx_fmt=png&amp;from=appmsg\" data-cropx2=\"1280.0000000000002\" data-cropy1=\"109.3238434163701\" data-cropy2=\"706.0498220640569\" data-imgfileid=\"100136949\" data-ratio=\"0.46640625\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_jpg/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcxxHKG0vjoziaey1SiblMdClBhe0F5ialThNxJM1O0aJTMaTN1HhAofkcQ/640?wx_fmt=jpeg\" style=\"width: 1080px;height:262px;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   索托克拉今年已先后向中国 NMPA 递交了 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （CLL/SLL）\n   </span>\n   、套细胞淋巴瘤\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （MCL）\n   </span>\n   的上市申请，并被纳入优先审评。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   未来，百济神州还将针对索托克拉进行广泛开发，并计划注册申报多种适应症，包括华氏巨球蛋白血症\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （WM）\n   </span>\n   、多发性骨髓瘤\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （MM）\n   </span>\n   、急性髓系白血病\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （AML）\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"326\" data-backw=\"578\" data-imgfileid=\"100136951\" data-ratio=\"0.56328125\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcyHET4ZK4Dwg5CFaiaXoTjQq9PLMiaqHWZVodiapcpUbiaOZDOYsNYia6x1Q/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在 B 细胞恶性肿瘤领域，除了前述产品，百济神州还开发了 T 细胞衔接器药物、细胞治疗药物、巨噬细胞衔接器。其中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    首款细胞治疗产品 CD19-CAR iγδT\n   </span>\n   旨在解决与同种异体 CAR-T 细胞相关的持久性问题，预计在 2026 年进入临床试验阶段。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"316\" data-backw=\"578\" data-imgfileid=\"100136952\" data-ratio=\"0.54609375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcYZMulFFTlRPDc7Hbiad0gqM8BrrLkZiciaZ5ZNYjB6sMUw0wK4j7xniabw/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   总而言之，在血液瘤领域，百悦泽仅仅只是开始，百济神州正在建立更完善的血液产品组合。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;text-align: center;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"52\" data-backw=\"463\" data-imgfileid=\"502448861\" data-ratio=\"0.11296296296296296\" data-type=\"png\" data-w=\"1080\" height=\"52\" src=\"/static/res/logo/https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZaqU9L6wBSPRicxbyNQUGkONWicTcnJOwMEFTtWTw62FMicjoVatWfAvaicG6L4TcSgNlgR0Q54oPWYdg/640?wx_fmt=png&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;vertical-align: bottom;color: rgba(0, 0, 0, 0.9);font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 1080px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;background-color: rgb(255, 255, 255);font-family: 等线;font-size: 16px;letter-spacing: 0.578px;box-sizing: border-box !important;overflow-wrap: break-word !important;height: auto !important;width: 1080px !important;visibility: visible !important;\" width=\"463\"/>\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    实体瘤产品组合\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在实体瘤领域，百济神州也开发了丰富的产品管线，包括小分子抑制剂、ADC、单抗、双抗、三抗、降解剂等等，拟用于治疗\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    乳腺癌/妇科癌、肺癌、胃肠道癌\n   </span>\n   等疾病领域。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"266\" data-backw=\"578\" data-imgfileid=\"100136953\" data-ratio=\"0.46015625\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcA8cycMvNW9tZokUSBYHpbN7jjTe2xQeTJSn6A1pHhEqnoZvPVGdxEA/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;color: rgb(0, 180, 200);background-color: rgb(255, 255, 255);'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    乳腺癌及妇科癌症管线\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在乳腺癌及妇科癌症领域，百济神州开发的药物类型主要包括：\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    细胞周期调节药物、雌激素受体药物、ADC、免疫细胞衔接器\n   </span>\n   。其中，有 3 款已进入 IND 阶段，CDK4 抑制剂有望于 2025 年底前启动首个关键性临床研究。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"327\" data-backw=\"578\" data-imgfileid=\"100136954\" data-ratio=\"0.565625\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcFAB5lgWSzMUWHax4TrOj4zTf9J70F2IBzmexb7cYqVRsHOTs4JEe6A/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BGB-43395 是一款选择性 CDK4 抑制剂，可避免 CDK6 抑制和脱靶毒性。在与氟维司群联用研究中已展示出良好的耐受性、改善的血液学耐受性，以及初步的抗肿瘤活性。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"322\" data-backw=\"578\" data-imgfileid=\"100136956\" data-ratio=\"0.55703125\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcdny54xI8YlX23aSIjPV00ufLiaBMEsQqIqRvMa3Qfv4QavqsFquJzNQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BG-C9074\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （B7-H4 ADC）\n   </span>\n   <span style=\"color: rgb(0, 0, 0);\" textstyle=\"\">\n    是\n   </span>\n   针对表达 B7-H4 肿瘤患者的潜在同类首创 ADC。早期临床数据显示，BG-C9074 单药治疗在临床相关剂量水平下耐受性良好。在乳腺癌和妇科癌中观察到令人信服的早期抗肿瘤活性。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"318\" data-backw=\"578\" data-imgfileid=\"100136957\" data-ratio=\"0.55\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcIrp3Y1yPUib2icYT3LIONqArGu7CFIffoC91qaezPoibOmxfN2o7iafdPQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BG-68501 是一款 CDK2 抑制剂，在实体瘤\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （包括对 CDK4/6 抑制剂耐药的乳腺癌）\n   </span>\n   中与CDK4 抑制剂联用具有潜在协同作用。目前，BG-68501 单药治疗乳腺癌已显现出早期活性。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"263\" data-backw=\"578\" data-imgfileid=\"100136958\" data-ratio=\"0.4546875\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPc6O6hphzFn7yz9wgj8vGibythqLpWbToC23ianxJEicdHtz7129iaic4k0YQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   另外两款产品 BG-75098（CDK2 CDAC）和 BG-75202（KAT6A/B 抑制剂），预计在 2025 年底前进入临床。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;color: rgb(0, 180, 200);background-color: rgb(255, 255, 255);'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    肺癌管线\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   肺癌领域，百济神州开发的管线主要包括\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    MTAP 缺失药物、EGFR 突变药物、KRAS 突变药物、ADC\n   </span>\n   四类。其中有 3 款已进入 IND 阶段，包括 EGFR×MET×MET 三特异性 ADC、RAS（ON）抑制剂、ADAM9 ADC。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   PRMT5 抑制剂和 MAT2A 抑制剂是 MTAP 缺失 NSCLC 和其他 MTAP 缺失肿瘤的潜在治疗药物。百济神州是目前唯一一家同时拥有临床阶段 PRMT5 抑制剂（BGB-58067）和 MAT2A 抑制剂（BG-89894）的公司，两个项目均处于单药治疗剂量递增研究阶段。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"317\" data-backw=\"578\" data-imgfileid=\"100136959\" data-ratio=\"0.5484375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcaHt3yuJRSZohfic4HVyEbuCw16JVGBOjjYeMKTXb9F1hich2ulaeP5Mg/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p data-pm-slice=\"13 2 []\" style=\"line-height: 1.75em;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;color: rgb(0, 180, 200);background-color: rgb(255, 255, 255);'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    胃肠道癌管线\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在胃肠道癌领域，百济神州的管线包括 KRAS 药物、MTAP 缺失药物、EGFR 药物、ADC、免疫细胞衔接器。其中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    KRAS CDAC、可穿透血脑屏障的 RAS（ON）抑制剂预计将于 2026 年下半年进入临床\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"322\" data-backw=\"578\" data-imgfileid=\"100136960\" data-ratio=\"0.55703125\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcSVOmZ5Op8qicUxfLK7PlxVzDKJXkZy9NEB2EDdeG1AvuibpXNyWAH7Ew/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   总体来看，百济神州已在短短两年内彻底重塑其临床阶段实体瘤产品组合，在乳腺癌/妇科癌、肺癌、胃肠道癌在三大疾病领域实现产品组合内药物联用\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    。针对每个疾病领域，百济神州都在每年持续推出 2~3 种新的临床阶段分子\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-bottom: 8px;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"52\" data-backw=\"463\" data-imgfileid=\"502448861\" data-ratio=\"0.11296296296296296\" data-type=\"png\" data-w=\"1080\" height=\"52\" src=\"/static/res/logo/https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZaqU9L6wBSPRicxbyNQUGkONWicTcnJOwMEFTtWTw62FMicjoVatWfAvaicG6L4TcSgNlgR0Q54oPWYdg/640?wx_fmt=png&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp\" style=\"-webkit-tap-highlight-color: transparent;margin-top: 0px;margin-right: 0px;margin-left: 0px;padding: 0px;outline: 0px;max-width: 100%;vertical-align: bottom;color: rgba(0, 0, 0, 0.9);font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 1080px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;text-align: center;background-color: rgb(255, 255, 255);font-family: 等线;font-size: 16px;letter-spacing: 0.578px;box-sizing: border-box !important;overflow-wrap: break-word !important;height: auto !important;width: 1080px !important;visibility: visible !important;\" width=\"463\"/>\n  </span>\n </p>\n <p data-mpa-action-id=\"mceghf8da23\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mceghf7k1hgg\" style=\"line-height: 1.75em;text-align: center;font-size: 17px;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    预期里程碑事件\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mceg0ffd10p4\" leaf=\"\" style=\"font-size: 15px;\">\n   展望未来 18 个月，百济神州将有望迎来多个关键后期催化剂和关键早期催化剂事件。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mceg0ffd10p4\" leaf=\"\" style=\"font-size: 15px;\">\n   2025 下半年，百悦泽 MANGROVE TN MCL Ⅲ 期 PFS 期中分析结果预计将会读出，百泽安 1L NPC、辅助/新辅助 NSCLC 预计将在欧盟获批，BTK CDAC CaDAnCe-304 R/R CLL 头对头对比匹妥布替尼 Ⅲ 期将启动。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mceg0ffd10p4\" leaf=\"\" style=\"font-size: 15px;\">\n   另外，泛 KRAS 抑制剂、EGFR CDAC、B7-H3 ADC、CEA ADC、FGFR2b ADC、IRAK4 CDAC 等多个在研管线将在今年下半年迎来概念验证数据读出。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"313\" data-backw=\"562\" data-imgfileid=\"100136961\" data-ratio=\"0.55703125\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcf2jV2oahEkxGTulgGDvibhQZokiaILoewZxWIX98suD7e9bqDUktrqtQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width:100%;\" type=\"block\"/>\n </section>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"316\" data-backw=\"578\" data-imgfileid=\"100136962\" data-ratio=\"0.54609375\" data-s=\"300,640\" data-type=\"png\" data-w=\"1280\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcIW82kQI72qhGcm1YREK9x6m6icNicQwp9zMMlaDmmWLejfwbPEfbkY1Q/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <section>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcehnqvfpq4\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mcehnquup1v\" style=\"font-size: 12px;line-height: 1em;margin-bottom: 8px;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    参考资料：\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcehnqvfpq4\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mcehnquup1v\" style=\"font-size: 12px;line-height: 1em;margin-bottom: 8px;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    [1]\n   </span>\n  </span>\n  <span leaf=\"\">\n   <a class=\"normal_text_link\" data-itemshowtype=\"0\" data-linktype=\"2\" href=\"https://mp.weixin.qq.com/s?__biz=MzA3OTIxOTkyMw==&amp;mid=2257529256&amp;idx=1&amp;sn=67778ff3f4ed2b26a37a206acde0284e&amp;color_scheme=light&amp;scene=21#wechat_redirect\" linktype=\"text\" style=\"color: rgb(178, 178, 178);\" target=\"_blank\" textvalue=\"百济神州在研发日展示开创性肿瘤治疗管线\">\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     百济神州在研发日展示开创性肿瘤治疗管线\n    </span>\n   </a>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcehnqvfpq4\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mcehnquup1v\" style=\"font-size: 12px;\">\n  <section data-mpa-action-id=\"mcehnqvfpq4\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mcehnquup1v\" style=\"font-size: 12px;line-height: 1em;margin-bottom: 8px;margin-left: 8px;margin-right: 8px;\">\n   <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"section\",\"attributes\":{\"mpa-font-style\":\"mcehnquup1v\",\"style\":\"font-size: 12px;\",\"data-mpa-action-id\":\"mcehnqvfpq4\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\">\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     [2]百济神州研发日 PPT。\n    </span>\n   </span>\n  </section>\n </section>\n <section data-mpa-action-id=\"m9uot5bs375\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span style=\"outline: 0px;font-size: 12px;visibility: visible;color: rgb(163, 163, 163);\">\n   <strong style=\"outline: 0px;letter-spacing: 0.544px;visibility: visible;\">\n    <span leaf=\"\">\n     封面来源：\n    </span>\n   </strong>\n   <span style='outline: 0px;visibility: visible;font-family: -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;'>\n    <span leaf=\"\">\n     企业 Logo\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"m9uot5bsqdr\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span style=\"outline: 0px;font-size: 15px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     免责声明：\n    </span>\n   </strong>\n   <span style=\"outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"m9uot5bs1bys\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <section data-mpa-action-id=\"m9uot5bs1hf5\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;font-size: 12px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span leaf=\"\">\n     编辑\n    </span>\n   </strong>\n   <span leaf=\"\">\n    ：馨药\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"m9uot5bs1aof\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      PR 稿对接\n     </span>\n    </span>\n   </strong>\n   <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"m9uot5bs228m\" style='margin-right: 8px;margin-bottom: 24px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      投稿\n     </span>\n    </span>\n   </strong>\n   <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb；邮箱 insight@dxy.cn\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"m9uot5bs1jhe\" nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 0px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133180\" data-ratio=\"0.6319148936170212\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBzyf7pyZ00Jj17v3UdI4lHwH4Wr619icjjBYhbcBFjPCc9Jkib4472Piag/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n </section>\n <section>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <p style=\"display: none;\">\n  <mp-style-type data-value=\"3\">\n  </mp-style-type>\n </p>\n</div>\n",
  "publish_time": 1751068800,
  "mp_id": "MP_WXS_3975077766",
  "pic_url": "https://mmbiz.qlogo.cn/mmbiz_jpg/lVFg8Ny0F8ucW2Ee8hvn51urJYO5sDPcSectSeMRACZ2YJ2l3Yywoqic5USAUJW5hedFoVlywUZ514V4JHo50icA/0?wx_fmt=jpeg",
  "mp_name": "Insight数据库"
}